Table 1.

Deterministic company and ERG base-case results

Assumed effectiveness of DEX	Analysis	Comparator	Fully incremental ICER (incremental £/QALY)	ICER of FAc versus comparator
DEX not considered	Company base-case	(L)CP	–	£7183
HR of 0.456 for DEX versus (L)CP	ERG base-case 1	(L)CP	Cheapest	£12,325
		DEX	Extendedly dominated	£5335
		FAc	£12,325	–
	ERG base-case 2	(L)CP	Cheapest	£21,531
		DEX	Extendedly dominated	£9457
		FAc	£21,531	–
	ERG base-case 3	(L)CP	Cheapest	£19,049
		DEX	Extendedly dominated	£13,856
		FAc	£19,049	–
	ERG base-case 4	(L)CP	Cheapest	£30,153
		DEX	Extendedly dominated	£22,810
		FAc	£30,153	–
HR of 1 for DEX versus FAc (i.e. same effectiveness)	ERG base-case 1	(L)CP	Cheapest	£12,325
		DEX	£12,283	Dominated
		FAc	Dominated	–
	ERG base-case 2	(L)CP	Cheapest	£21,531
		DEX	£21,457	Dominated
		FAc	Dominated	–
	ERG base-case 3	(L)CP	Cheapest	£19,049
		DEX	£18,710	Dominated
		FAc	Dominated	–
	ERG base-case 4	(L)CP	Cheapest	£30,153
		DEX	£29,617	Dominated
		FAc	Dominated	–
HR of 0.7 for DEX versus FAc	ERG base-case 1	(L)CP	Cheapest	£12,325
		FAc	Extendedly dominated	–
		DEX	£10,412	£2297
	ERG base-case 2	(L)CP	Cheapest	£21,531
		FAc	Extendedly dominated	–
		DEX	£17,843	£3643
	ERG base-case 3	(L)CP	Cheapest	£19,049
		FAc	Extendedly dominated	–
		DEX	£17,239	£12,911
	ERG base-case 4	(L)CP	Cheapest	£30,153
		FAc	Extendedly dominated	–
		DEX	£25,074	£15,730

Sources: Tables 5.5 and 5.11–5.13 of the ERG report [3]

DEX dexamethasone, ERG Evidence Review Group, FAc fluocinolone acetonide, HR hazard ratio, ICER incremental cost-effectiveness ratio, (L)CP (limited) clinical practice, QALY quality-adjusted life-year